Mohammad Taheri M, Javan F, Poudineh M, Athari S
Clin Rev Allergy Immunol. 2024; 66(3):328-362.
PMID: 38995478
DOI: 10.1007/s12016-024-08998-0.
Munari S, Ciotti G, Cestaro W, Corsi L, Tonin S, Ballarin A
Drugs Context. 2024; 13.
PMID: 38817801
PMC: 11139165.
DOI: 10.7573/dic.2024-3-5.
Imamoto T, Kawasaki T, Sato H, Tatsumi K, Ishii D, Yoshioka K
Int J Mol Sci. 2024; 25(1).
PMID: 38203236
PMC: 10779039.
DOI: 10.3390/ijms25010066.
Hartung F, Esser-von Bieren J
Mucosal Immunol. 2022; 15(6):1158-1169.
PMID: 36065058
PMC: 9705254.
DOI: 10.1038/s41385-022-00557-0.
Chen S, Chen G, Xu F, Sun B, Chen X, Hu W
Cell Discov. 2022; 8(1):80.
PMID: 35973984
PMC: 9381771.
DOI: 10.1038/s41421-022-00433-y.
Recent advances of eosinophils and its correlated diseases.
Tao Z, Zhu H, Zhang J, Huang Z, Xiang Z, Hong T
Front Public Health. 2022; 10:954721.
PMID: 35958837
PMC: 9357997.
DOI: 10.3389/fpubh.2022.954721.
Treatment Resistance in Severe Asthma Patients With a Combination of High Fraction of Exhaled Nitric Oxide and Low Blood Eosinophil Counts.
Hoshino Y, Soma T, Uchida Y, Shiko Y, Nakagome K, Nagata M
Front Pharmacol. 2022; 13:836635.
PMID: 35517829
PMC: 9065285.
DOI: 10.3389/fphar.2022.836635.
Effects of inhaled corticosteroids (ICS) on lung microbiota and local immune response in long-term treatment of chronic obstructive pulmonary disease (COPD): utility of titration and therapeutic index.
Toraldo D, Rizzo E, Conte L
Naunyn Schmiedebergs Arch Pharmacol. 2022; 395(7):849-858.
PMID: 35435466
DOI: 10.1007/s00210-022-02237-z.
Different Phenotypes in Asthma: Clinical Findings and Experimental Animal Models.
Lourenco L, Ribeiro A, Lopes F, Tiberio I, Tavares-de-Lima W, Prado C
Clin Rev Allergy Immunol. 2021; 62(1):240-263.
PMID: 34542807
DOI: 10.1007/s12016-021-08894-x.
Targeted therapy in eosinophilic chronic obstructive pulmonary disease.
Fieldes M, Bourguignon C, Assou S, Nasri A, Fort A, Vachier I
ERJ Open Res. 2021; 7(2).
PMID: 33855061
PMC: 8039900.
DOI: 10.1183/23120541.00437-2020.
Adenovirus vector-mediated YKL-40 shRNA attenuates eosinophil airway inflammation in a murine asthmatic model.
Wang L, Bao A, Zheng Y, Ma A, Wu Y, Shang H
Gene Ther. 2020; 28(3-4):177-185.
PMID: 33046836
DOI: 10.1038/s41434-020-00202-0.
Anti-IL5 Therapies for Severe Eosinophilic Asthma: Literature Review and Practical Insights.
Menzella F, Ruggiero P, Ghidoni G, Fontana M, Bagnasco D, Livrieri F
J Asthma Allergy. 2020; 13:301-313.
PMID: 32982318
PMC: 7490042.
DOI: 10.2147/JAA.S258594.
Elevated Levels of Activated and Pathogenic Eosinophils Characterize Moderate-Severe House Dust Mite Allergic Rhinitis.
Chen Y, Yang M, Deng J, Wang K, Shi J, Sun Y
J Immunol Res. 2020; 2020:8085615.
PMID: 32855977
PMC: 7443015.
DOI: 10.1155/2020/8085615.
Interplay Between the IL-33/ST2 Axis and Bone Marrow ILC2s in Protease Allergen-Induced IL-5-Dependent Eosinophilia.
Boberg E, Johansson K, Malmhall C, Calven J, Weidner J, Radinger M
Front Immunol. 2020; 11:1058.
PMID: 32582171
PMC: 7280539.
DOI: 10.3389/fimmu.2020.01058.
Severe refractory asthma: current treatment options and ongoing research.
Menzella F, Bertolini F, Biava M, Galeone C, Scelfo C, Caminati M
Drugs Context. 2018; 7:212561.
PMID: 30534175
PMC: 6284776.
DOI: 10.7573/dic.212561.
Revisiting the NIH Taskforce on the Research needs of Eosinophil-Associated Diseases (RE-TREAD).
Khoury P, Akuthota P, Ackerman S, Arron J, Bochner B, Collins M
J Leukoc Biol. 2018; 104(1):69-83.
PMID: 29672914
PMC: 6171343.
DOI: 10.1002/JLB.5MR0118-028R.
Interleukin-25 and eosinophils progenitor cell mobilization in allergic asthma.
Tang W, Smith S, Du W, Gugilla A, Du J, Oliveria J
Clin Transl Allergy. 2018; 8:5.
PMID: 29456832
PMC: 5809891.
DOI: 10.1186/s13601-018-0190-2.
Understanding Interleukin 33 and Its Roles in Eosinophil Development.
Johnston L, Bryce P
Front Med (Lausanne). 2017; 4:51.
PMID: 28512632
PMC: 5411415.
DOI: 10.3389/fmed.2017.00051.